
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3727158/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks. Clinical Trials, 2022, 19, 402-406.	0.7	7
2	Quantifying the importance and location of SARS-CoV-2 transmission events in large metropolitan areas. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	35
3	Inferring high-resolution human mixing patterns for disease modeling. Nature Communications, 2021, 12, 323.	5.8	161
4	Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. Lancet Infectious Diseases, The, 2021, 21, 617-628.	4.6	192
5	Using simulated infectious disease outbreaks to inform site selection and sample size for individually randomized vaccine trials during an ongoing epidemic. Clinical Trials, 2021, 18, 630-638.	0.7	3
6	Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave. Nature, 2021, 600, 127-132.	13.7	61
7	Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials. Vaccine, 2020, 38, 7213-7216.	1.7	32
8	Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. Nature Human Behaviour, 2020, 4, 964-971.	6.2	605
9	Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study. The Lancet Global Health, 2020, 8, e1081-e1089.	2.9	26
10	COVID-19 vaccine trials should seek worthwhile efficacy. Lancet, The, 2020, 396, 741-743.	6.3	101
11	Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 1141-1150.	4.6	390
12	The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science, 2020, 368, 395-400.	6.0	2,784
13	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. New England Journal of Medicine, 2020, 382, 1366-1369.	13.9	63
14	Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. Lancet Infectious Diseases, The, 2020, 20, 793-802.	4.6	541
15	Design of vaccine efficacy trials during public health emergencies. Science Translational Medicine, 2019, 11, .	5.8	41
16	An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool. Vaccine, 2019, 37, 4376-4381.	1.7	11
17	Effects of infection history on dengue virus infection and pathogenicity. Nature Communications, 2019, 10, 1246.	5.8	26
18	Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine. Clinical Infectious Diseases, 2018, 66, 178-184.	2.9	28

#	Article	IF	CITATIONS
19	Seroprevalence of Dengue Antibodies in Three Urban Settings in Yucatan, Mexico. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1202-1208.	0.6	14
20	Quantifying the risk of local Zika virus transmission in the contiguous US during the 2015–2016 ZIKV epidemic. BMC Medicine, 2018, 16, 195.	2.3	11
21	Design of vaccine trials during outbreaks with and without a delayed vaccination comparator. Annals of Applied Statistics, 2018, 12, 330-347.	0.5	6
22	Transmissibility of Norovirus in Urban Versus Rural Households in a Large Community Outbreak in China. Epidemiology, 2018, 29, 675-683.	1.2	9
23	Spread of Zika virus in the Americas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4334-E4343.	3.3	249
24	Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet, The, 2017, 389, 505-518.	6.3	837
25	Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infectious Diseases, The, 2017, 17, 1276-1284.	4.6	79
26	Simulations for designing and interpreting intervention trials in infectious diseases. BMC Medicine, 2017, 15, 223.	2.3	64
27	Controlling cholera in the Ouest Department of Haiti using oral vaccines. PLoS Neglected Tropical Diseases, 2017, 11, e0005482.	1.3	7
28	Containing Ebola at the Source with Ring Vaccination. PLoS Neglected Tropical Diseases, 2016, 10, e0005093.	1.3	54
29	Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies. Vaccine, 2016, 34, 3796-3802.	1.7	4
30	One versus two doses: What is the best use of vaccine in an influenza pandemic?. Epidemics, 2015, 13, 17-27.	1.5	22
31	Increased Isolation Frequency of Toxigenic Vibrio cholerae O1 from Environmental Monitoring Sites in Haiti. PLoS ONE, 2015, 10, e0124098.	1.1	37
32	Cholera Transmission in Ouest Department of Haiti: Dynamic Modeling and the Future of the Epidemic. PLoS Neglected Tropical Diseases, 2015, 9, e0004153.	1.3	30
33	The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine, 2015, 33, 3293-3298.	1.7	109
34	Spatiotemporal spread of the 2014 outbreak of Ebola virus disease in Liberia and the effectiveness of non-pharmaceutical interventions: a computational modelling analysis. Lancet Infectious Diseases, The, 2015, 15, 204-211.	4.6	226
35	Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet, The, 2015, 386, 857-866.	6.3	715

36 Ebola and beyond. Science, 2015, 348, 46-48.

6.0 18

#	Article	IF	CITATIONS
37	School-Located Influenza Vaccination Reduces Community Risk for Influenza and Influenza-Like Illness Emergency Care Visits. PLoS ONE, 2014, 9, e114479.	1.1	25
38	Household Transmission of Vibrio cholerae in Bangladesh. PLoS Neglected Tropical Diseases, 2014, 8, e3314.	1.3	45
39	Assessing the International Spreading Risk Associated with the 2014 West African Ebola Outbreak. PLOS Currents, 2014, 6, .	1.4	251
40	Emerging, evolving, and established infectious diseases and interventions. Science, 2014, 345, 1292-1294.	6.0	18
41	Controlling Dengue with Vaccines in Thailand. PLoS Neglected Tropical Diseases, 2012, 6, e1876.	1.3	74
42	A Theoretic Framework to Consider the Effect of Immunizing Schoolchildren Against Influenza: Implications for Research. Pediatrics, 2012, 129, S63-S67.	1.0	17
43	Critical immune and vaccination thresholds for determining multiple influenza epidemic waves. Epidemics, 2012, 4, 22-32.	1.5	18
44	Planning for the Control of Pandemic Influenza A (H1N1) in Los Angeles County and the United States. American Journal of Epidemiology, 2011, 173, 1121-1130.	1.6	26
45	Design and Analysis of Vaccine Studies. Statistics in the Health Sciences, 2010, , .	0.2	189
46	The Transmissibility and Control of Pandemic Influenza A (H1N1) Virus. Science, 2009, 326, 729-733.	6.0	486
47	Detecting Human-to-Human Transmission of Avian Influenza A (H5N1). Emerging Infectious Diseases, 2007, 13, 1348-1353.	2.0	131
48	PUBLIC HEALTH: Community Studies for Vaccinating Schoolchildren Against Influenza. Science, 2006, 311, 615-616.	6.0	70
49	Mitigation strategies for pandemic influenza in the United States. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5935-5940.	3.3	904
50	Strategy for Distribution of Influenza Vaccine to High-Risk Groups and Children. American Journal of Epidemiology, 2005, 161, 303-306.	1.6	185
51	Containing Pandemic Influenza at the Source. Science, 2005, 309, 1083-1087.	6.0	1,044
52	Bioterrorism: the statistical issues. Significance, 2004, 1, 164-168.	0.3	0
53	Containing Pandemic Influenza with Antiviral Agents. American Journal of Epidemiology, 2004, 159, 623-633.	1.6	601
54	The critical vaccination fraction for heterogeneous epidemic models. Mathematical Biosciences, 2003, 181, 85-106.	0.9	94

#	Article	IF	CITATIONS
55	Epidemic and Endemic Cholera Trends over a 33‥ear Period in Bangladesh. Journal of Infectious Diseases, 2002, 186, 246-251.	1.9	131
56	Model-based estimation of vaccine effects from community vaccine trials. Statistics in Medicine, 2002, 21, 481-495.	0.8	27
57	A Frailty Mixture Model for Estimating Vaccine Efficacy. Journal of the Royal Statistical Society Series C: Applied Statistics, 1996, 45, 165.	0.5	73
58	Measuring vaccine efficacy from epidemics of acute infectious agents. Statistics in Medicine, 1993, 12, 249-263.	0.8	36